NEW YORK (GenomeWeb) – Roche announced today the inclusion of its Cobas HIV-1/HIV-2 nucleic acid test in its Global Access Program.

The CE-marked test enables health professionals to distinguish between HIV-1 and HIV-2 and provides users flexible PCR testing with serum, plasma, and validated dried blood spot (DBS) collection card sample types to improve treatment options based on subtype infections in rural locations, Roche said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.